Mepsevii: Uses, Dosage & Side Effects

What Is Mepsevii and What Is It Used For?

Mepsevii contains the active substance vestronidase alfa, a recombinant form of the human lysosomal enzyme beta-glucuronidase (GUS). This enzyme is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. Beta-glucuronidase is a critical lysosomal hydrolase that catalyzes the cleavage of terminal beta-D-glucuronic acid residues from the non-reducing end of glycosaminoglycans (GAGs), specifically dermatan sulfate, heparan sulfate, and chondroitin 4,6-sulfate. When this enzyme is absent or severely deficient, these complex sugar molecules accumulate progressively within lysosomes throughout the body, leading to cellular dysfunction, tissue damage, and ultimately the clinical manifestations of MPS VII.

Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, was first described by Dr. William S. Sly and colleagues in 1973. It is classified as an ultra-rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GUSB gene located on chromosome 7q11.21. This gene encodes the beta-glucuronidase enzyme. To date, more than 60 different pathogenic variants have been identified in the GUSB gene, including missense mutations, nonsense mutations, splice-site variants, and small insertions or deletions. The type of mutation and the residual enzyme activity it allows are important determinants of clinical severity, contributing to the remarkably broad phenotypic spectrum of MPS VII.

The clinical presentation of MPS VII is extraordinarily variable, ranging from severe hydrops fetalis in utero (the most severe form, often resulting in stillbirth or neonatal death) to a mild, attenuated phenotype with later onset and slower progression. Most patients with the intermediate or attenuated forms present in infancy or early childhood with some combination of the following features: skeletal abnormalities (dysostosis multiplex), short stature, hepatosplenomegaly (enlarged liver and spleen), coarse facial features, corneal clouding, cardiac valve disease, recurrent respiratory infections, hernias, hearing loss, and variable degrees of cognitive impairment. The progressive nature of GAG accumulation means that symptoms tend to worsen over time without treatment, leading to increasing disability and reduced quality of life.

MPS VII is estimated to have a prevalence of fewer than 1 in 250,000 to 1 in 1,000,000 live births, making it one of the rarest of all mucopolysaccharidoses. Fewer than 200 cases have been reported in the medical literature worldwide. Due to its extreme rarity and variable presentation, MPS VII is frequently underdiagnosed or misdiagnosed, and the average time from symptom onset to correct diagnosis can span many years. Diagnosis typically involves demonstrating elevated urinary GAG levels, reduced beta-glucuronidase enzyme activity in leukocytes or fibroblasts, and confirmatory molecular genetic testing of the GUSB gene.

Vestronidase alfa works through a mechanism known as receptor-mediated cellular uptake. After intravenous infusion, the recombinant enzyme circulates in the bloodstream and is taken up by cells throughout the body via mannose-6-phosphate (M6P) receptors on cell surfaces. The M6P tag on the enzyme directs it to lysosomes, where it can catalyze the hydrolysis of accumulated GAGs. By providing a functional source of beta-glucuronidase, Mepsevii helps to clear the backlog of undegraded substrate within lysosomes, thereby reducing cellular dysfunction and potentially halting or slowing the progression of disease-related organ damage.

The pivotal evidence for Mepsevii's efficacy came from a Phase 3 randomized, placebo-controlled clinical trial (Study UX003-CL301), which enrolled 12 patients with MPS VII aged 5 to 35 years. This was a blind-start study design, where patients were randomized to begin active treatment at different predetermined time points, effectively serving as their own controls. The primary endpoint was the Multi-Domain Responder Index (MDRI), a composite measure assessing six clinically meaningful domains: pulmonary function (forced vital capacity), 6-minute walk test distance, shoulder range of motion (flexion), visual acuity, fatigue (assessed by the Bruininks-Oseretsky Test), and urinary dermatan sulfate levels. Results demonstrated that treatment with vestronidase alfa led to rapid and sustained reductions in urinary GAG levels (the key pharmacodynamic biomarker), with many patients also showing improvements in walking endurance, pulmonary function, and other domains.

Mepsevii was granted orphan drug designation by both the FDA (2012) and EMA (2012), as well as breakthrough therapy designation by the FDA, reflecting the severity and rarity of MPS VII and the unmet medical need. It was approved by the FDA on November 15, 2017, and by the European Commission on August 23, 2018, making it the first and, as of this writing, the only approved treatment specifically indicated for MPS VII.

What Should You Know Before Taking Mepsevii?

Contraindications

There are no absolute contraindications listed for Mepsevii in the FDA prescribing information or EMA SmPC, as the severity of MPS VII and the lack of alternative treatments mean that the benefit-risk balance strongly favors treatment in virtually all diagnosed patients. However, patients who have experienced life-threatening anaphylactic reactions to vestronidase alfa that cannot be adequately managed with appropriate medical interventions should not receive further infusions without careful risk-benefit assessment and consultation with an allergist or immunologist.

The excipients in Mepsevii include sodium dihydrogen phosphate monohydrate, sodium chloride, histidine, histidine hydrochloride monohydrate, polysorbate 20, and water for injection. Patients with known hypersensitivity to any of these components should inform their healthcare provider prior to treatment initiation.

Warnings and Precautions

Before starting and during treatment with Mepsevii, the following precautions should be carefully considered:

• Infusion-associated reactions (IARs): IARs are among the most common adverse events observed with Mepsevii. They may include fever, chills, headache, rash, urticaria, pruritus, flushing, nausea, vomiting, abdominal pain, diarrhea, fatigue, erythema, and elevated body temperature. IARs can range from mild to severe and may occur during or within several hours after the infusion. Pre-treatment with antihistamines, antipyretics (such as paracetamol/acetaminophen), and/or corticosteroids may help reduce the frequency and severity of IARs. If a severe IAR occurs, the infusion rate should be slowed or temporarily stopped, and appropriate symptomatic treatment should be administered.
• Immunogenicity and anti-drug antibodies: As a recombinant protein, vestronidase alfa has the potential to elicit an immune response. The majority of patients in clinical trials developed anti-drug antibodies (ADAs) to vestronidase alfa. In some cases, neutralizing antibodies have been detected. The clinical significance of ADAs is not fully understood, but high antibody titers may theoretically reduce the efficacy of the enzyme or increase the risk of hypersensitivity reactions. Healthcare providers should monitor patients for signs of reduced clinical response or increased frequency of infusion reactions, which could indicate clinically significant immunogenicity.
• Acute febrile or respiratory illness: Patients who have an acute febrile illness at the time of a scheduled infusion should be carefully evaluated. The decision to proceed with the infusion should be made on a case-by-case basis by the treating physician, considering the severity of the illness and the urgency of treatment.
• Spinal cord compression: Spinal cord compression is a known complication of MPS VII and other mucopolysaccharidoses, resulting from GAG deposition in the spinal canal, vertebral abnormalities, or instability of the cervical spine. Mepsevii is not expected to resolve existing spinal cord compression. Patients should be monitored for signs and symptoms of spinal cord compression (such as back pain, limb weakness, urinary incontinence, or gait changes) and referred for neurosurgical evaluation if indicated.

Use in Children

Mepsevii is approved for use in pediatric patients. MPS VII frequently presents in infancy or early childhood, and early initiation of enzyme replacement therapy is considered beneficial to reduce GAG accumulation before irreversible organ damage occurs. In clinical trials, patients as young as 5 years of age were enrolled. Experience in patients younger than 5 years is limited but growing, and the recommended dose (4 mg/kg every two weeks) is the same for children and adults. Pediatric patients should be monitored carefully during and after infusions, as children may be at higher risk for certain infusion-associated reactions.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Mepsevii use in pregnant women. Animal reproductive toxicity studies have not been conducted with vestronidase alfa. As a recombinant human protein (an IgG-like molecule in terms of its M6P-mediated uptake mechanism, though not an antibody), vestronidase alfa may cross the placenta, particularly during the second and third trimesters. The potential risks to the developing fetus are unknown. Given the rarity of MPS VII and the severity of the untreated disease, the decision to use Mepsevii during pregnancy should be made on an individual basis after careful discussion between the patient and their healthcare provider, weighing the potential benefits of treatment against the unknown risks to the fetus.

It is not known whether vestronidase alfa is excreted in human breast milk. Many therapeutic proteins are present in breast milk at low concentrations, and oral bioavailability of proteins is generally very low due to degradation in the infant's gastrointestinal tract. The decision to breastfeed while receiving Mepsevii should be made in consultation with the healthcare provider, considering the benefits of breastfeeding for the infant and the benefits of continued treatment for the mother.

Driving and Operating Machinery

Mepsevii is not expected to directly affect the ability to drive or operate machinery. However, some infusion-associated reactions (such as dizziness, fatigue, or headache) may temporarily impair alertness. Patients should be advised not to drive or operate heavy machinery if they experience such symptoms following an infusion until they have fully recovered.

How Does Mepsevii Interact with Other Drugs?

One of the practical aspects of enzyme replacement therapy, including Mepsevii, is that these products are large recombinant proteins that are metabolized through general catabolic pathways (proteolysis) rather than through the hepatic cytochrome P450 (CYP) enzyme system. This fundamental difference from small-molecule drugs means that traditional pharmacokinetic drug-drug interactions mediated by CYP enzyme inhibition, induction, or competition are not expected.

No formal drug interaction studies have been conducted with vestronidase alfa. Population pharmacokinetic analyses from the clinical trial program did not identify any significant effects of concomitant medications on vestronidase alfa pharmacokinetics. Similarly, vestronidase alfa is not expected to alter the metabolism or clearance of other drugs.

Patients with MPS VII often require a range of concomitant medications and treatments to manage the multisystem complications of their disease. These may include:

While no pharmacokinetic interactions are anticipated, there is a theoretical consideration regarding immunosuppressive therapies. Some patients with high anti-drug antibody titers may be considered for immunomodulatory protocols (such as methotrexate or rituximab) to reduce the immune response to vestronidase alfa. The decision to use immunosuppressive agents in conjunction with Mepsevii should be made by experienced metabolic disease specialists, balancing the need for effective enzyme replacement against the risks of immunosuppression, particularly in patients who may already be prone to infections due to their underlying disease.

As a general principle, patients should always inform their healthcare providers about all medications, supplements, and herbal products they are taking. This allows for comprehensive monitoring and ensures that any unexpected adverse interactions, however unlikely, can be promptly identified and addressed.

What Is the Correct Dosage of Mepsevii?

Mepsevii must always be used exactly as prescribed by your healthcare provider. It is a hospital-based or clinic-based treatment that requires intravenous access and specialized monitoring during and after each infusion. Unlike some medications that can be self-administered at home, Mepsevii must be given by or under the direct supervision of a healthcare professional experienced in the management of patients with lysosomal storage disorders or other inherited metabolic diseases.

Adults

The recommended dose for adult patients is 4 mg/kg administered as an intravenous infusion once every two weeks (every 14 days). The total infusion time should be approximately 4 hours. The infusion rate should be gradually increased during each session according to the recommended infusion rate schedule, provided the patient tolerates the infusion well:

The infusion rate may be slowed, temporarily stopped, or the infusion discontinued at the discretion of the supervising healthcare professional if any infusion-associated reaction occurs. For patients who have experienced previous IARs, slower infusion rates and extended infusion times may be used. The infusion rate should never exceed the maximum recommended rate.

Children

The recommended dose for pediatric patients is the same as for adults: 4 mg/kg administered by intravenous infusion once every two weeks. MPS VII is a disease that typically presents in childhood, and early initiation of enzyme replacement therapy is considered advantageous to reduce GAG accumulation before irreversible tissue damage occurs. In the pivotal clinical trial, patients as young as 5 years of age were enrolled and received the same weight-based dose. Pediatric patients may require additional care and monitoring during infusions, including age-appropriate pre-medication protocols and the involvement of pediatric nursing staff experienced in intravenous infusion procedures.

Elderly Patients

Due to the ultra-rare nature of MPS VII, clinical experience with Mepsevii in elderly patients (aged 65 years and older) is extremely limited. The severe forms of MPS VII often result in significant morbidity in childhood and young adulthood, meaning that relatively few patients survive to older age. For any elderly patients who may require treatment, the standard dose of 4 mg/kg every two weeks is recommended, with careful monitoring for age-related comorbidities that may affect infusion tolerance, such as cardiovascular or renal disease.

Missed Dose

If a scheduled infusion is missed, it should be administered as soon as reasonably possible. The subsequent infusion schedule should then resume at two-week intervals from the date of the make-up infusion. Patients and caregivers should work with their treatment center to reschedule missed infusions promptly, as delays in treatment may allow GAG levels to increase and potentially lead to clinical deterioration. Regular adherence to the biweekly infusion schedule is important for maintaining optimal treatment outcomes.

Overdose

There is no specific antidote for vestronidase alfa overdose. In clinical trials, single doses of up to 8 mg/kg were administered to some patients without dose-limiting toxicity. In the event of an overdose, the patient should be monitored closely for any signs or symptoms of adverse reactions, and appropriate symptomatic and supportive care should be provided. Given the short elimination half-life of vestronidase alfa (approximately 35–38 minutes), elevated plasma levels would be expected to decline rapidly.

Preparation and Administration

Mepsevii is supplied as a clear to slightly opalescent, colorless to pale yellow sterile solution for intravenous infusion in single-use vials containing 10 mg of vestronidase alfa in 5 mL (2 mg/mL). The required number of vials should be determined based on the patient's body weight and the 4 mg/kg dose. The total volume of vestronidase alfa should be diluted in 0.9% sodium chloride solution to a final volume appropriate for intravenous infusion. The diluted solution should be administered using an infusion set equipped with a 0.2 micron in-line filter. The solution must not be mixed with other medicinal products in the same infusion line.

What Are the Side Effects of Mepsevii?

Like all enzyme replacement therapies for lysosomal storage disorders, Mepsevii can cause side effects. The safety profile of vestronidase alfa has been evaluated in clinical trials involving patients with MPS VII, as well as in post-marketing surveillance. The most frequently reported adverse events are infusion-associated reactions (IARs), which are related to the immune response to the exogenous recombinant enzyme. Not everyone who receives Mepsevii will experience side effects, and many patients tolerate the infusions well with appropriate pre-treatment and monitoring.

The following is a summary of reported side effects organized by frequency category, based on data from clinical trials and post-marketing experience:

It is important to understand the distinction between infusion-associated reactions and true anaphylaxis. Anaphylaxis is a severe, potentially life-threatening systemic allergic reaction that typically involves multiple organ systems (skin, respiratory, cardiovascular, and/or gastrointestinal) and may include symptoms such as severe hypotension, airway compromise, widespread urticaria, and angioedema. Anaphylaxis requires immediate treatment with epinephrine (adrenaline) and other resuscitative measures. In clinical trials, anaphylaxis was reported in a significant proportion of patients, which is why the boxed warning on the prescribing information emphasizes the need for appropriate medical support during every infusion.

Most non-anaphylactic infusion reactions are IgG-mediated rather than IgE-mediated and typically respond to slowing or temporarily stopping the infusion, combined with administration of antihistamines, corticosteroids, and/or antipyretics. Over time, some patients may develop tolerance and experience fewer or milder reactions with successive infusions, particularly if consistent pre-medication protocols are used.

The development of anti-drug antibodies (ADAs) is common with Mepsevii, as with other enzyme replacement therapies. In the clinical trial program, the majority of patients developed ADAs during treatment. The presence of ADAs may be associated with an increased risk of infusion reactions and may potentially affect the pharmacokinetics and clinical efficacy of the enzyme. However, the relationship between ADA titers and clinical outcomes has not been definitively established, and most patients continued to receive clinical benefit despite the presence of antibodies.

If you experience any side effects, including those not listed here, inform your healthcare provider. Reporting side effects helps to build a more complete safety profile for this medication, which is particularly important for ultra-rare disease treatments where the total treated population is small and long-term data continue to accumulate.

How Should You Store Mepsevii?

Proper storage of Mepsevii is essential to maintain the stability and efficacy of the recombinant enzyme. As a biological product, vestronidase alfa is sensitive to temperature extremes, physical agitation, and light exposure, all of which can cause protein denaturation and loss of enzymatic activity.

The following storage conditions apply to unopened Mepsevii vials:

• Temperature: Store at 2–8 °C (36–46 °F) in a refrigerator. Do not freeze. If the product has been frozen, do not use it.
• Light protection: Store in the original carton to protect from light. Do not expose vials to direct sunlight or strong artificial light.
• Physical handling: Do not shake or agitate the vials. Vigorous shaking can cause foaming and protein aggregation, which may reduce the efficacy of the product and increase the risk of immunogenicity.
• Expiration: Do not use beyond the expiration date printed on the carton and vial label. Each vial is for single use only; discard any unused portion.

Once the concentrate has been diluted for intravenous infusion in 0.9% sodium chloride, the solution should ideally be used immediately. If immediate use is not possible, the diluted solution may be stored at 2–8 °C for up to 36 hours, including the time of infusion. Alternatively, the diluted solution may be stored at room temperature (up to 25 °C / 77 °F) for up to 4 hours. The diluted solution should not be re-refrigerated once it has been warmed to room temperature. During the infusion, the diluted solution should be protected from direct light.

Healthcare facilities responsible for storing and preparing Mepsevii should ensure that cold chain integrity is maintained from receipt of the product through preparation and administration. Any vials that have been exposed to temperatures outside the recommended range, have been frozen, or show visible particulate matter, cloudiness, or discoloration should not be used and should be discarded in accordance with local pharmaceutical waste disposal guidelines.

Keep all medicines, including Mepsevii, out of the sight and reach of children. Do not dispose of medicines via household waste or wastewater. Return any unused or expired medicines to your pharmacist or healthcare facility for proper disposal.

What Does Mepsevii Contain?

Mepsevii is a sterile, preservative-free solution for intravenous infusion. Understanding the composition of the medication is important for identifying potential allergens and for healthcare providers preparing the infusion.

Vestronidase alfa is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is a glycosylated protein with a molecular weight of approximately 75 kDa per monomer. The enzyme forms a homotetramer (four identical subunits) in its active form, with a total molecular weight of approximately 300 kDa. The recombinant enzyme contains mannose-6-phosphate (M6P) residues on its glycan chains, which are essential for cellular uptake via M6P receptors and subsequent delivery to lysosomes where the enzyme exerts its therapeutic effect.

The solution appears clear to slightly opalescent, colorless to pale yellow. Small translucent particles may be present and do not affect the quality or safety of the product. However, the solution should not be used if it is visibly cloudy, significantly discolored, or contains large particulate matter. Prior to dilution, the vial should be gently inverted to ensure homogeneity; vigorous shaking should be avoided as it may cause protein denaturation and aggregation.

Mepsevii does not contain any preservatives and each vial is intended for single use only. Any unused product remaining in the vial after dose withdrawal should be discarded. The product does not contain latex, gluten, or any components derived from animal or human blood products (other than the recombinant CHO-derived protein itself).